What is Eli Lilly's cash and cash equivalents, end of period?

Eli Lilly (LLY) reported cash and cash equivalents, end of period of $5.28B in Q1 2026.

How has Eli Lilly's cash and cash equivalents, end of period changed year-over-year?

Eli Lilly's cash and cash equivalents, end of period increased by 70.8% year-over-year, from $3.09B to $5.28B.

What is the long-term trend for Eli Lilly's cash and cash equivalents, end of period?

Over 5 years (2020 to 2025), Eli Lilly's cash and cash equivalents, end of period has grown at a 14.7% compound annual growth rate (CAGR), from $3.66B to $7.27B.

What does cash and cash equivalents, end of period mean?

The total amount of cash and highly liquid assets held by the company, including restricted funds.

Other

Cash and cash equivalents, end of period

Eli Lilly Cash and cash equivalents, end of period decreased by 27.3% to $5.28B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 70.8%, from $3.09B to $5.28B. Over 5 years (FY 2020 to FY 2025), Cash and cash equivalents, end of period shows an upward trend with a 14.7% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.

Analysis

StatementBalance Sheet Statement

SectionOther

CategoryLiquidity

SignalHigher is better

VolatilityModerate

First reportedQ4 2022

Last reportedQ1 2026

How to read this metric

Higher levels indicate strong liquidity and readiness to meet claims, whereas lower levels may signal a need for capital raising or asset liquidation.

Detailed definition

This represents the total liquidity available to the company, including highly liquid assets and cash that may be subjec...

Peer comparison

Insurance companies typically maintain high levels of cash and equivalents to satisfy regulatory liquidity requirements.

Metric ID: other_cash_cash_equivalents_restricted_cash_and_restrict_5675e1

Historical Data

20 periods

	Q2 '21	Q3 '21	Q4 '21	Q1 '22	Q2 '22	Q3 '22	Q4 '22	Q1 '23	Q2 '23	Q3 '23	Q4 '23	Q1 '24	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26
Value	$3.22B	$3.79B	$3.82B	$2.46B	$2.62B	$2.62B	$2.07B	$3.55B	$2.69B	$2.38B	$2.82B	$2.46B	$3.22B	$3.37B	$3.27B	$3.09B	$3.38B	$9.79B	$7.27B	$5.28B
QoQ Change	—	+17.6%	+0.8%	-35.6%	+6.7%	-0.2%	-21.0%	+71.5%	-24.0%	-11.6%	+18.4%	-12.7%	+31.0%	+4.5%	-3.0%	-5.4%	+9.1%	+190.1%	-25.8%	-27.3%
YoY Change	—	—	—	—	-18.5%	-30.9%	-45.9%	+44.2%	+2.7%	-9.0%	+36.4%	-30.6%	+19.6%	+41.5%	+15.9%	+25.7%	+4.7%	+190.6%	+122.4%	+70.8%

Range$2.07B – $9.79B

CAGR+11.0%

Avg YoY Growth+27.5%

Median YoY Growth+17.8%

Current Streak2 quarters decline

Cash and cash equivalents, end of period at Other Companies

Roivant SciencesROIV View metric

Frequently Asked Questions

What is Eli Lilly's cash and cash equivalents, end of period?: Eli Lilly (LLY) reported cash and cash equivalents, end of period of $5.28B in Q1 2026.
How has Eli Lilly's cash and cash equivalents, end of period changed year-over-year?: Eli Lilly's cash and cash equivalents, end of period increased by 70.8% year-over-year, from $3.09B to $5.28B.
What is the long-term trend for Eli Lilly's cash and cash equivalents, end of period?: Over 5 years (2020 to 2025), Eli Lilly's cash and cash equivalents, end of period has grown at a 14.7% compound annual growth rate (CAGR), from $3.66B to $7.27B.
What does cash and cash equivalents, end of period mean?: The total amount of cash and highly liquid assets held by the company, including restricted funds.